Source: WRAL TECHWIRE, 8/31/20

BioCryst Pharmaceuticals has landed a $44 million contract to see if its investigational anti-viral drug, galidesivir, is effective in treating the COVID-19 coronavirus. The Durham-based pharmaceutical firm today confirmed it received the new investment from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, along with an additional $3 million to an existing contract dating back to 2015.

For more of this story, click here.